Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer headquartered in Jerusalem, Israel, for the month of April 2021. The filing, dated April 15, 2021, consists solely of a press release (Exhibit 99.1) incorporated by reference. The document serves to update investors on material events and is incorporated into the company's registration statements on Form F-3.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this report contains only a press release and not a financial statement, no specific financial metrics are disclosed within this document.
Material Changes
The filing does not contain comparative financial data or a discussion of material changes versus prior periods. The content is limited to the announcement of the press release itself.
Guidance, Outlook, and Risks
Specific guidance, outlook, management commentary, risks, contingencies, or unusual items are not detailed in the provided text. The filing references a press release for these details but does not include the text of that release. The document confirms the company files annual reports under Form 20-F.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K referencing an external press release dated April 15, 2021.
- No financial data (revenue, cash, debt) is included in this specific document.
- Investors must review Exhibit 99.1 (the press release) to understand the specific material event or announcement.
- The company is authorized to file under Form 20-F.